A case of metastatic renal cell carcinoma showing complete remission after cytoreductive nephrectomy followed by temsirolimus

被引:0
|
作者
Naotaka Nishiyama
Naoya Masumori
机构
[1] Sapporo Medical University School of Medicine,Department of Urology
关键词
Poor-risk renal cell carcinoma; Temsirolimus; Complete remission;
D O I
10.1007/s13691-016-0261-y
中图分类号
学科分类号
摘要
Here, we present a case report of a patient with poor-risk advanced renal cell carcinoma who had a complete remission after cytoreductive nephrectomy followed by temsirolimus. A 67-year-old woman was diagnosed with advanced renal cell carcinoma, stage pT3aN2M1 in April 2013. In the Memorial Sloan-Kettering Cancer Center criteria, she had three prognostic factors and was classified into the poor-risk category. After 23 weeks of treatment with temsirolimus, complete remission was achieved. Temsirolimus treatment was discontinued after 23 weeks because of grade 3 toxicity noninfectious pneumonitis. Five months after beginning steroid treatment without temsirolimus, a CT scan showed no new metastatic lesion or progression of disease. This was a very rare case with achievement of a complete remission after cytoreductive nephrectomy followed by temsirolimus.
引用
收藏
页码:4 / 7
页数:3
相关论文
共 50 条
  • [41] Cytoreductive nephrectomy for metastatic renal cell carcinoma in the presence of nonconventional histology
    Kassouf, Wassim
    Sanche-Ortiz, Ricardo
    Tamboli, Pheroze
    Jonasch, Eric
    Merchant, Madhur M.
    Matin, Surena
    Swanson, David A.
    Wood, Christopher G.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 366 - 366
  • [42] Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?
    Vives Dilme, Roser
    Gomez Rivas, Juan
    Campi, Riccardo
    Puente, Javier
    Jerez, Tamara
    Enikeev, Dmitry
    Esperto, Francesco
    Moreno Sierra, Jesus
    CURRENT UROLOGY REPORTS, 2021, 22 (11)
  • [43] Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
    Renner, Alex
    Samtani, Suraj
    Marin, Arnaldo
    Burotto, Mauricio
    JOURNAL OF KIDNEY CANCER AND VHL, 2019, 6 (01): : 1 - 7
  • [44] Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?
    Roser Vives Dilme
    Juan Gómez Rivas
    Riccardo Campi
    Javier Puente
    Tamara Jerez
    Dmitry Enikeev
    Francesco Esperto
    Jesús Moreno Sierra
    Current Urology Reports, 2021, 22
  • [45] CYTOREDUCTIVE TREATMENT IN METASTATIC RENAL CELL CARCINOMA: IS NEPHRECTOMY THE ONLY OPTION?
    Bolgeri, Marco
    Emara, Amr
    Barber, Neil J.
    JOURNAL OF ENDOUROLOGY, 2012, 26 : A299 - A300
  • [46] What is the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?
    Yanagisawa, Takafumi
    Schmidinger, Manuela
    Fajkovic, Harun
    Karakiewicz, Pierre I.
    Kimura, Takahiro
    Shariat, Shahrokh F.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (05) : 455 - 459
  • [47] Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma
    Rabets, JC
    Kaouk, J
    Fergany, A
    Finelli, A
    Gill, IS
    Novick, AC
    UROLOGY, 2004, 64 (05) : 930 - 934
  • [48] Utilization of Partial Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma
    Hauser, Nicholas
    Giakas, Julian
    Robinson, Hunter
    Davaro, Facundo
    Hamilton, Zachary
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (19)
  • [49] The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the modern era
    Fortuna, Gliceida M. Galarza
    Maughan, Benjamin L.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (05) : 915 - 919
  • [50] RISK CLASSIFICATION TO PREDICT SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Shinohara, Nobuo
    Abe, Takashige
    Maruyama, Satoru
    Sazawa, Ataru
    Nonomura, Katsuya
    JOURNAL OF UROLOGY, 2012, 187 (04): : E723 - E723